Aceto

We demonstrate the wide range of customized products and services that Actylis offers its biopharma customers.

We showcase Actylis, what the company stands for and how we serve our broad-ranging customer base globally.

We look at the importance of finding suppliers able to develop and customise Process Intermediates to meet the rapidly-changing expectations of modern finished drug manufacturers, and the economic & logistic benefits of outsourcing Buffer manufacturing, especially with the rise of cell & gene therapy products.

We demonstrate the wide range of customized products and services that Actylis offers its biopharma customers.

In this whitepaper we explore the role of GMP-grade Phenylmethylsulfonyl fluoride and other protease inhibitors in biopharmaceutical manufacturing, and we outline how Actylis’ high-purity and refined PMSF helps finished drug manufacturers to meet increasingly rigorous regulatory requirements.

We provide a list of readily available high-quality biopharma ingredients used for in vitro diagnostics, vaccines, cell cultures and preservatives that we keep on hand to service our biopharma customers. All these raw materials have a very short lead time to suit your rapidly-changing manufacturing needs.

Our in-house experts, along with Cecile Bellamy from Pfizer, deep dive into the factors that are influencing our industry today and look at what trends are likely to impact us in the future. We cover topics including regulatory compliance, manufacturer flexibility & supply chain risk and debate the supplier vs partner relationship and the importance of collaboration as we face a challenging future.

We showcase Actylis, what the company stands for and how we serve our broad ranging customer base globally.

Our in-house experts, along with Cecile Bellamy from Pfizer, deep dive into the factors that are influencing our industry today and look at what trends are likely to impact us in the future. We cover topics including regulatory compliance, manufacturer flexibility & supply chain risk and debate the supplier vs partner relationship and the importance of collaboration as we face a challenging future.